Status: Recruiting
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after first-line chemotherapy. Eligible patients will be assigned to liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT. The total sample size for this study is expected to be 56 subjects.
Participants needed: 56
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolUpdated: Feb 6, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years and ≤ 75 years, ECOG score of ≤2 points, expected survival time ≥... [+3]
Have received second-line or more anti-tumor therapy in the past. [+3]